COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao provide an update on data specific to COVID in rheumatologic disease patients. @jeffsparks @drdavidliew @KDAO2011 #ACR21 https://t.co/IzDIpe5IrU https://t.co/6i8C3Grw9q

• https://bit.ly/3mRhBvz

apart from that, fibrosis is fascinating - as is the potential for a shared fibrotic pathway #ACR21 Antifibrotics session @RheumNow https://t.co/FXbhBx9sJ1

@ericdeinmd Although the MTX/alopecia - nausea poster was interesting. Abst#1444 #ACR21 Factors assc w/MTX- nausea/alopecia: 👉female sex 👉EtOH use 👉higher disease activity 👉belief that the med will cause it (older age assc w/⬇️risk of nausea) https://t.co/XDKFhvN0V1 @rheumnow

• Baseline Factors Associated with the Development of Nausea and Alopecia over On…

#ACR21 Ab#1445. RTX & #covid19 outcomes ⭐️RTX ass. w/ Upwards arrow COVID hospitalization, ICU admission, and ventilation ▶️We need huge caution in pts that have not been vax'ed before RTX 💉💉 @Rheumnow https://t.co/6UNUVhnBkI https://t.co/vHkQe9fZpI

• https://bit.ly/3qk9MB2

#ACR21 Ab#1036. Rheum is often the field of uncertainty. @zach_wallace_md shows uncertainty correlates w/ depression, anxiety, sickness impact across rheum diseases ⭐️Is uncertainty something to target as intervention? @Rheumnow https://t.co/v9kbk2hCqO https://t.co/50ELS3ZQp9

• https://bit.ly/3wFMiaJ

So what do we do with Iberdomide data? Tough to analyze re 2nd half of yr1 and uncertainty of dose response Abst#1458 #ACR21 @RheumNow v low placebo response 35% Interesting https://t.co/JXnoJTy2tv

Among 6 CV risk algorithms, the best to predict the carotid plaque (CP) in PsA is the ACC/AHA risk score showed an AUC 0.681 (0.551-0.812), p=0.008, a cut-off point ≥4.8, sensitivity of 63.6%, and specificity of 64.4% ⭐️Prevalence CP 42.3% Abst #1315 #ACR21 @RheumNow https://t.co/hRvyjetYq3

I thought pirfenidone was just an anti-fibrotic - the spectrum of its MOA is actually fascinating @ErinWilfongMD #ACR21 Antifibrotics session, chaired by @JuliePaikMD @RheumNow https://t.co/oMZOtfAUq0

RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its faculty.

DCVAS testing results in GCA. @davidliew @philipcrobinson are you guys essentially not imaging anyone in anyway? What's going on? #ACR21 @RheumNow https://t.co/IMr5ee2Iea